Author

T. Colpitts

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Research Focus:cell type annotation· 1 Assay:multiome· 1

Frequent Co-Authors

A. Carfi· 3 shared H. Bennett· 3 shared A. Choi· 2 shared D. K. Edwards· 2 shared K. Wu· 2 shared M. Koch· 2 shared A. B. McDermott· 1 shared A. Hill· 1 shared

Activity by Year

2021-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

A. Carfi

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

A monkeypox mRNA-lipid nanoparticle vaccine targeting virus binding, entry, and transmission drives protection against lethal orthopoxviral challenge

A. W. Freyn, C. Atyeo, P. L. Earl, J. L. Americo, G.-Y. Chuang, H. Natarajan, T. R. Frey, J. Gall, J. I. Moliva, R. Hunegnaw, G. Asthagiri Arunkumar, C. Ogega, A. Nasir, H. Bennett, J. Johnson, , B. Moss

This paper develops an mRNA-lipid nanoparticle vaccine targeting four conserved MPXV surface proteins, showing superior protection against VACV compared to MVA.

bioRxiv · Dec 17, 2022 · PreprintImmunology

Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants

A. Choi, M. Koch, K. Wu, G. Dixon, J. Oestreicher, H. Legault, G. B. E. Stewart-Jones, T. Colpitts, R. Pajon, H. Bennett, A. Carfi, D. K. Edwards

This study evaluates the neutralizing activity of mRNA-1273 vaccine-induced sera against SARS-CoV-2 variants, finding reduced but still effective neutralization against several variants compared to the wild-type virus.

bioRxiv · Jun 28, 2021Microbiology

Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice

K. Wu, A. Choi, M. Koch, S. Elbashir, L. Ma, D. Lee, A. Woods, C. Henry, C. Palandjian, A. Hill, H. Jani, J. Quinones, N. Nunna, S. O'Connell, A. B. McDermott, , D. K. Edwards

This study evaluates updated SARS-CoV-2 mRNA vaccines in mice, showing that mRNA-1273.351 boosts neutralization against B.1.351 and mRNA-1273.211 provides broad cross-variant protection.

bioRxiv · Apr 13, 2021Microbiology